|Bid||89.75 x 1200|
|Ask||89.83 x 800|
|Day's Range||88.61 - 90.04|
|52 Week Range||68.80 - 90.04|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||48.92|
|Earnings Date||Jan 21, 2020|
|Forward Dividend & Yield||1.44 (1.62%)|
|Ex-Dividend Date||Jan 12, 2020|
|1y Target Est||95.68|
Biotech news flow remained light last week, although there were some notable developments such as FDA panel reviews of opioid pain drugs, a few clinical data readouts, presentations and updates at the ...
Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.
Seven years ago, the two big China tech giants introduced mobile payments for the exchange of cash gifts—so-called red envelopes. Now the pair continue to compete to increase and engage users.
The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.
Earnings season looms next year at a key point for the market. U.S. stocks are at all-time highs, and need a strong batch of earnings reports to keep the momentum going.Source: Shutterstock That's particularly true for the three stocks featured in Friday's big stock charts. Technically, all three names have clear potential for big moves in the next few weeks. In each case, an important upcoming earnings report represents a catalyst. * 10 Cheap Stocks to Buy Under $10 To be sure, it's not 100% clear in which direction these stocks will head. But for investors willing to firmly pick a side, or traders looking for potential volatility, these big stock charts should be watched closely in the coming weeks.InvestorPlace - Stock Market News, Stock Advice & Trading Tips International Business Machines (IBM)Source: Provided by Finviz IBM (NYSE:IBM) is trying to rally ahead of its fourth quarter earnings report on Tuesday afternoon. But while the first of Friday's big stock charts suggests some cause for optimism, recent history suggests reason for caution: * Technically, IBM stock is at least set up for a rally. Shares have exited a narrowing wedge to the upside, and cleared near-term moving averages in the process. The 200-day moving average has provided resistance that IBM stock will need to move through, but a strong fourth quarter report could provide the required boost. * A strong report is necessary. IBM's acquisition of Red Hat closed in July, and was supposed to allow IBM to finally get back to growth. The company infamously went 22 consecutive quarters without generating year-over-year revenue growth, and returned to declines after breaking the streak in 2017. As a result, IBM stock has gained just 4.7% total over the past decade, while the S&P 500 has nearly tripled. * And so this is an important reason on multiple fronts. The 2020 outlook, which includes a full year of Red Hat, needs to be strong enough to inspire confidence. The chart both reflects and amplifies the fundamental importance of the quarter: trading in IBM stock next week seems likely to set its direction for some time to come. There's a path to challenge July highs around $150 with a beat, and a potential reversal to $125 if IBM disappoints once again. Abbott Laboratories (ABT)Source: Provided by Finviz Abbott Laboratories (NYSE:ABT) has posted much more impressive multi-year performance: shares in fact have more than doubled since late 2016. But resistance has been stiff of late, and Abbott Labs likely needs a strong fourth quarter report on Wednesday morning to break out: * ABT stock certainly is gearing up for another run, with strong performance in recent sessions on decent volume. An uptrend has held since early October and investors quickly bought a small, brief dip last week. For now, anyway, shares certainly are headed in the right direction. * Here, too, it likely takes a strong fourth quarter report for the stock to break out. Abbott will not only detail Q4 results next week, but will give guidance for 2020. Wall Street projects about 11% growth in earnings per share this year, a reasonably high bar to clear. It's too simplistic to argue that ABT will rise if guidance exceeds expectations and falls if it doesn't -- but it doesn't seem too far off. At the least, the second of our big stock charts suggests it will be exceedingly difficult to break out if Abbott can't deliver an above-consensus outlook. * Some help from the market would be useful as well. Abbott unquestionably is a wonderful company, recently increasing its dividend for the 48th consecutive year. But like most wonderful companies in this market, valuation is a question mark: the 24x forward multiple is historically high. If Abbott can deliver a big report next week, that multiple will be less of an issue. If it simply matches expectations, it will need investors to keep paying up for quality. FuelCell Energy (FCEL)Source: Provided by Finviz FuelCell Energy (NASDAQ:FCEL) has been one of the market's best stocks in the past seven months, gaining over 1,500% from late June lows. And the third of Friday's big stock charts suggests the rally could have another leg: * Technically, FCEL stock has established a classic flag formation, with the parabolic gain the "flagpole" and the sideways trading since the flag. Those patterns are continuation patterns, which often lead to another bounce higher after the stock consolidates. A recent "golden cross," in which the 50-day moving average moves above the 200-day, adds to the bullishness shown on the chart. * Click to Enlarge Source: Provided by Finviz That said, taking the broader view, the risks become apparent simply from the chart. Amazingly, FCEL stock is down 65.5% over the past year even after the enormous rally of late. It has declined 98.6% in the last five years. FuelCell Energy has delivered optimism before, but it's always disappointed. * And so FuelCell's fourth quarter report, also on Wednesday, looks exceedingly important. FCEL stock is trying to follow the path of fellow (if different) fuel cell play Plug Power (NASDAQ:PLUG), which has re-inspired investor confidence over the last year. A new agreement with Exxon Mobil (NYSE:XOM) and a game-changing loan agreement seem to have de-risked the story. If FuelCell Energy can deliver a positive quarter and a strong outlook next week, the rally can and should continue.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Stocks to Buy Under $10 * 5 Retail Stocks Placer.ai Thinks Can Win Big in 2020 * 6 Cheap Stocks to Buy Under $7 The post 3 Big Stock Charts for Friday: IBM, Abbott Labs, and FuelCell Energy appeared first on InvestorPlace.
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The start of the annual J.P. Morgan Healthcare Conference in San Francisco this week brought with it a number of funding announcements, including five from Bay Area startups and another from a new venture firm launched by a former Kleiner Perkins partner. Here are the details of those deals and others that were disclosed at the start of the week.
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved a first-of-its-kind clinical trial that will compare the effectiveness of Abbott's minimally invasive MitraClip™ device – which has now treated 100,000 patients worldwide – to open heart mitral valve surgical repair in people with primary mitral regurgitation (MR) who are eligible for open-heart surgery. If successful, the trial has the potential to expand treatment options for patients who are suffering from leaking mitral valves and whose current options are limited to open-heart surgery.
Dexcom stock is the IBD Stock Of The Day after shares of the diabetes treatment specialist broke out of a flat base to a record high. Dexcom makes devices for patients with diabetes.
Abbott Laboratories disclosed Wednesday that Chief Financial Officer Brian Yoor has said he will retire, effective Feb. 29. He was named to his current position as executive vice president and CFO in February 2017. The drug and medical products company said it named Controller Robert Funck as CFO, effective March 1. The stock rose 0.4% in morning trading. It has rallied 26.2% over the past 12 months, while the SPDR Health Care Select Sector ETF has advanced 17.3% and the S&P 500 has climbed 26.1%.
ABT stock is one of the biggest diversified medical stocks behind Johnson & Johnson and Roche. As it aims for clearance of its Freestyle Libre 2 system, is it time to buy Abbott stock?
Abbott's (ABT) less invasive approach for heart surgery for its heart pump gets the FDA clearance, thus paving the way for avoiding open heart surgeries.
The alternative surgery method can result in less bleeding during surgery and shorter recovery time for patients.
Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval of a new alternative surgical technique for Abbott's HeartMate 3 heart pump that will allow more advanced heart failure patients to avoid open heart surgery. The new, less invasive approach is designed to provide surgeons a choice in surgical method for patients receiving the HeartMate 3™ Left Ventricular Assist Device (LVAD), the industry's leading heart pump.
China’s central bankers gave U.S. investors a gift to start the new year: more economic stimulus in the Middle Kingdom.
Boston Scientific Corp. could be forced to go through with a $275 million acquisition that the Marlborough-based medical device giant had abandoned following a fraud investigation.
The Zacks Analyst Blog Highlights: Facebook, Alibaba, Mastercard, Abbott Laboratories and Philip Morris International
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]